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INTRODUCTION
Telomerase, a ribonucleoprotein enzyme that consists of
RNA and protein, can synthesize telomeres. Normally, some
telomerase is found in germ cells and hemopoietic cells, but
not in normal somatic cells. However, malignant cells gain
the ability to proliferate indefinitely because telomerase is
usually active in them (1). Telomerase activity has been stud-
ied as a cancer-diagnosing indicator and a prognostic factor
that helps to predict the progress of malignant tumors (2, 3).
Telomerase consists of three important components of hu-
man telomerase RNA (hTR), telomerase-associated protein
1 (TP1), and human telomerase reverse transcriptase (hTERT)
(4, 5). The hTERT mRNA is a catalytic subunit protein of
telomerase, which harbors the enzymatic activity of telom-
erase (4). A very strong correlation between the presence of
hTERT mRNA and telomerase activity has been generally
accepted, although direct evidence is scarce. hTR and TP1
are broadly expressed in both cancers and in normal tissues
and their expression is not significantly correlated with telom-
erase activity (6-8). 
An understanding of how telomerase activity is regulated
in vivo is important not only to understand the molecular
biology of telomerase, but also because of its potential as a
possible target molecule for anticancer drugs. A combined
regimen of cisplatin and 5-fluorouracil (5-FU) is used main-
ly for head and neck malignant tumors including hypopha-
ryngeal cancer and laryngeal carcinoma (9). An understand-
ing of the mechanism of inhibiting telomerase activity with
these drugs would provide valuable information on how telo-
merase is regulated in vivo. This study evaluated the telom-
erase activity and quantified the expression of hTERT mRNA
and hTR using a real-time reverse transcriptase-polymerase
chain reaction (RT-PCR) method before and after the expo-
sure of cisplatin and 5-FU in head and neck cancer cell lines.
MATERIALS AND METHODS
Cancer cell lines 
The laryngeal carcinoma cell line (SNU-899) was purchas-
ed from the Korean Cell Line Bank (10). PNUH-12 cells
originating from hypopharyngeal squamous cell carcinoma
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Change of the Expression of Human Telomerase Reverse Transcriptase
mRNA and Human Telomerase RNA after Cisplatin and 5-Fluorouracil
Exposure in Head and Neck Squamous Cell Carcinoma Cell Lines 
Telomerase activity appears to be associated with cell immortalization and malig-
nant progression. Understanding how telomerase activity is regulated in vivo is im-
portant not only for understanding the molecular biology of telomerase but also for
the potential clinical application of anticancer drugs. This study evaluated telome-
rase activity and quantified the expression of human telomerase reverse transcrip-
tase (hTERT) mRNA and human telomerase RNA (hTR) using a real-time reverse
transcriptase-polymerase chain reaction (RT-PCR) method before and after the
exposure of cisplatin and 5-fluorouracil (5-FU) in two head and neck squamous cell
carcinoma (HNSCC) cell lines. Two human HNSCC cell lines (PNUH-12 and SNU-
899) were studied. Cell cytotoxicity, the change of telomerase activity, and hTERT
mRNA and hTR expression by 5-FU and cisplatin exposure were assessed by MTT
assay, TRAP assay, and real-time RT-PCR, respectively. In two cell lines, after cis-
platin exposure, the telomerase activity and hTERT mRNA expression decreased,
but hTR expression in- creased according to the concentration of drug. However, in
both cell lines, the telomerase activity and hTR did not show any significant change
after 5-FU treatment, but the expression of hTERT mRNA decreased. These results
suggest that there may be other important regulating mechanism except hTERT
mRNA as the regulation factor of telomerase activity in HNSCC cell lines. 
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were established at the Department of Otolaryngology, Col-
lege of Medicine, Pusan National University (11). PNUH-
12 cells, a p53 mutant-type (one point mutation at the 78th
base, C to G, in exon 7) human hypopharyngeal squamous
cell carcinoma cell line, were maintained as a monolayer in
Dulbecco’s Modified Eagle medium (DMEM, GIBCO BRL,
Grand Island, NY, U.S.A.) containing 10% (v/v) fetal bovine
serum, 100 units/mL penicillin and 100 mg/mL streptomy-
cin and were incubated at 37℃in a humidified atmosphere
of 5% CO2. 
Anticancer drugs 
The study used cisplatin (Dong-A, Pharmaceutical Co.,
Seoul, Korea) and 5-FU (Choongwae Pharmaceutical Co.,
Seoul, Korea), which are widely used for the treatment of
malignant head and neck cancer. 
Cell cytotoxicity assay (MTT Assay) 
Cytotoxicities to cisplatin and 5-FU were assessed by MTT
(3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) assay. Briefly, 200  L of cell suspension (1×104 cells)
was added to each well of 96-well flat-bottom microtitre
plates (Costar, Cambrige, Massachusetts, U.S.A.), and each
plate was incubated for 24 hr at 37℃ in a humidified 5%
CO2 atmosphere. After incubation, drugs were made up in
the medium, and various concentrations were added to the
plates at a volume of 200  L per well. The plates were incu-
bated for 48 hr with the drugs. Following incubation, 100  L
of MTT working solution (2 mg/mL, Sigma Chemical Co.,
St. Louise, MO, U.S.A.) was added to each well and incu-
bated for 4 hr at 37℃. The medium was carefully discard-
ed, and the formazan crystals were dissolved in 100  L di-
methylsulphoxide. The absorbance of each well was mea-
sured with a microculture plate reader (Emax) at 570 nm.
Absorbance values were expressed as a percentage of untreat-
ed controls and an inhibition concentration 50 (IC50) was
calculated. The IC50 value represents the mean of at least
four independent experiments.
Measurements of telomerase activity and analysis by the
TRAP method 
The activity of telomerase was measured and examined
with using a TRAPEZE Telomerase Detection Kit (Intergen
Co. NY, U.S.A.) using the TRAP assay by Kim et al. (1).
Cells before and after treatment with anticancer drugs were
put in a microcentrifuge tube and 100  L of 1X CHAPS
lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM
EGTA, 0.1 mM benzamidine, 5 mM  -mercaptoethanol,
0.5% CHAPS, 10% Glycerol) was added. Then a homoge-
neous solution was made by pipetting. This solution was
kept in ice for 30 min before undergoing centrifusion. App-
roximately 80  L of the top-layer solution was moved into a
new tube, and the protein concentration was measured. The
protein concentration was then diluted with a 1X CHAPS
lysis buffer to make 1  g/ L.
The TS primer (5′ -AATCCGTCGAGCAGAGTT-3′ ) to
be used for the TRAP reaction was labeled with  -32P-ATP
(3,000 Ci/mM, 10  Ci/mL) and T4 polynucleotide kinase.
The total amount of the TRAP reaction solution was 25  L:
2.5  L of the 10X TRAP buffer (200 mM Tris-HCl, pH 8.3,
15 mM MgCl2, 630 mM KCl, 0.5% Tween 20, 10 mM EG-
TA, 0.1% BSA), 0.5  L of the 50X dNTPs mix (25 mM
each of dATP, dTTP, dGTP and dCTP), 1  L of the 32P-TS
primer, 0.5  L of the TRAP primer mix (RP primer, K1
primer, TSK1 template), 0.2  L of Taq polymerase (5 units/
L, Takara Co., Shiga, Japan), 18.3  L of distilled water,
and 2  L of the specimen. The solution was reacted at 30℃
for 30 min in a thermal cycler (Mastercycler 5330, Eppen-
dorf Co., Hamburg, Germany), so that the telomerase in
the specimen could react. Next, the reaction was terminated
by heating for 30 sec at 94℃. The amplification of the prod-
uct of reaction was repeated 30 times; one unit of amplifica-
tion consisted of 30 sec at 94℃and 30 sec at 60℃.
Loading dye (0.25% bromophenol blue, 0.25% xylene
cyanol, 50% glycerol, 50 mM EDTA, pH 8.0) was put into
each reaction tube, and electrophoresis was conducted in
12.5% polyacrylamide gel and 0.25X TBE buffer. The results
were analyzed by using a phosphorimager (Molecular Dyna-
mics Co., Sunnyvale, CA, U.S.A.). 
Total RNA extraction 
RNA was extracted using RNAzolBTM (WAK-Chemie
Medical, Bad Homburg, Germany) according to the manu-
facture’s instructions. The RNA yield was quantified by UV
spectrophotometry. One microgram of total RNA was sub-
jected to 1% agarose gel electrophoresis. Preservation of 28S
and 18S rRNA species was used to assess the RNA integrity. 
Quantitative detection of hTERT mRNA by real time RT-
PCR
Quantitative detection of hTERT mRNA was performed
with the commercially available LightCycler Telo TAGGG
hTERT Quantification Kit (Roche Diagnostics GmbH, Ma-
nnheim, Germany) using the LightCycler instrument (Roche
Molecular Systems, Alameda, CA, U.S.A.) for real-time PCR
and all subsequent quantification steps according to the man-
ufacturer’s instructions. These experiments were repeated
three times for each cell line.
hTERT mRNA was reverse transcribed, and a fragment
of the cDNA were amplified with specific primers in a one-
step RT-PCR reaction. The amplicon was detected by fluo-
rescence using a specific pair of hybridization probes. The
hybridization probes consisted of two different short oligonu-cleotides that hybridized to an internal sequence of the am-
plicon during the annealing phase of the amplification cycle.
One probe was labeled at the 5′ -end with LightCycler Red
640 and, to avoid extension, modified at the 3′ -end by phos-
phorylation. The other probe was labeled at the 3′ -end with
fluorescein. The two probes were in close proximity only
after hybridization to the template DNA, resulting in fluo-
rescence resonance energy transfer (FRET) between the two
fluorophores. During FRET, fluorescein, the donor fluoro-
phore, was excited by the light source of the LightCycler
instrument, and part of the excitation energy was transferred
to LightCycler Red 640, the acceptor fluorophore. The emit-
ted fluorescence of LightCycler Red 640 was then measured
by the LightCycler instrument. 
A typical 20  L one-tube RT-PCR reaction contained 200
ng of total RNA (sample) or standard RNA templates pro-
vided with the kit. mRNA was reverse-transcribed for 10
min at 60℃. PCR amplifications were performed in sepa-
rate tubes for 40 cycles (0.5 sec at 95℃; 10 sec at 60℃; 10
sec at 72℃) using manufacturer-supplied reaction mixtures
specific for hTERT or the housekeeping gene PBGD, respec-
tively. The PBGD reaction product served as a control for RT-
PCR and as a reference for relative quantification of hTERT
mRNA.
The number of PCR cycles to reach the fluorescence thresh-
old was the cycle threshold (Ct). The Ct value for each sam-
ple was proportional to the log of the initial amount of input
cDNA. By plotting the Ct value of an unknown sample on
the standard curve, the amount of target sequences in the
sample could be calculated. To normalize the hTERT mRNA
expression for sample to sample differences in RNA input,
RNA quality, and reverse transcriptase efficiency, we ampli-
fied the housekeeping gene PBGD. From each standard
curve, we derived the copy numbers of PBGD and hTERT,
respectively. The ratio between the copy numbers of hTERT
and PBGD represented the normalized hTERT (NhTERT)
for each sample and could be compared with that of other
samples. 
NhTERT=hTERT mRNA copies sample/PBGD mRNA
copies sample 
Quantitative detection of hTR by real-time RT-PCR 
The quantitative detection of hTR was performed using
the same procedures described for hTERT, in combination
with the LightCycler Telo TAGGG hTR Quantification Kit
(Roche Diagnostics GmbH). Because the hTR-encoding
gene is intron-free, the PCR products could result from con-
tamination by genomic DNA. These experiments were re-
peated three times for each cell line.
The number of PBGD and hTR transcripts in samples was
calculated with the LightCycler software, using these stan-
dard curves. Each sample was normalized on the basis of its
PBGD content (see above) according to the formula NhTR=
hTR mRNA copies sample/PBGD mRNA copies sample. 
RESULTS
Cell cytotoxicity test 
After the treatment of cisplatin and 5-FU in PNUH-12
and SNU-899, the cell survival rate decreased in proportion
to concentration. The IC50 difference between cisplatin and
5-FU in PNUH-12 and SNU-899 were 8-fold and 15-fold,
respectively (Fig. 1). 
Telomerase activity by the TRAP assay
The trap assay was conducted in PNUH-12 and SNU 899
before drug treatment, and the activity of telomerase was dis-
played (Fig. 2). In both cell lines, after cisplatin exposure,
telomerase activity decreased according to the drug concen-
tration, but after 5-FU exposure, the change of telomerase
activity was insignificant. 
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Fig. 1. Cytotoxic effects of cisplatin (A) and 5-fluorouracil (5-FU) (B) in PNUH-12, SNU-899, and HEp-2. As the concentration of the cisplatin
and 5-FU increased, the survival decreased. 
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Real-time RT-PCR in PNUH-12
We used different concentrations of hTERT and hTR stan-
dard templates including 103, 104, 105, 106, and 107 copies/
2  L to perform quantitative PCR and calculate the standard
curves, respectively. The correlation coefficients were both
1.00. 
After cisplatin exposure in PNUH-12 and SNU-899, the
expression of hTERT mRNA decreased, and the manifesta-
tion of hTERT mRNA also decreased after 5-FU exposure
(Fig. 3). The expression of hTR increased after cisplatin ex-
posure but did not show any significant change after 5-FU
exposure in either cell lines (Fig. 4). 
DISCUSSION
A very strong correlation between telomerase expression
and the presence of detectable hTERT mRNA has been ac-
cepted (4, 5). A high concentration of hTERT mRNA was
detected in a cell with a high expression of telomerase activi-
ty. Though Akiyama et al. (12) reported that loss of telom-
erase activity was associated with a reduced catalytic domain
(hTERT) mRNA level, the direct mechanism of hTERT
mRNA related to telomerase regulation is unclear. More-
over, Cressey et al. (13) reported that reduced hTERT mRNA
was produced by doxorubicin despite the lack of any effect
on telomerase activity. Although hTR acts as a matrix to
extend telomere, its expression is not significantly correlat-
Fig. 3. Detection of hTERT mRNA in PNUH-12 (A) and SNU-899 (B) samples by real-time RT-PCR analysis using the LightCycler. Concomi-
tant detection of PBGD mRNA served as a reference for relative quantification. The normalized hTERT mRNA levels decreased after cis-
platin and 5-fluorouracil (5-FU) exposure in both cell lines.
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Fig. 2. Photographs showing the telomerase activity of three head and neck cancer cell lines by cisplatin and 5-fluorouracil (5-FU) exposure.
Telomerase activity was observed by telomerase assay in PNUH-12 (A) and SNU-899 (B) cell lines. The telomerase activity decreased in
a concentration-dependent manner after cisplatin exposure, while the change in telomerase activity was insignificant after 5-FU exposure. 
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ed with telomerase activity (7, 8).
This study examined the hTERT mRNA and hTR exp-
ression using real-time RT-PCR for the measurement of quan-
tity and telomerase activity before and after the treatment of
cisplatin and 5-FU in SNU-899 and PNUH-12. After cis-
platin treatment, the telomerase activity and hTERT mRNA
expression decreased, but hTR expression increased in both
cell lines. Although telomerase activity did not show any
significant change after 5-FU exposure, the expression of
hTERT mRNA decreased and the expression of hTR did
not show any significant change. The decrease in telomerase
activity was not related to the decrease in numbers of cells
as a percentage of viable cells.
Although Cressey et al. (13) reported that telomerase activ-
ity was not a reliable indicator of chemosensitivity in human
testicular cancer cells, cisplatin may be more effective in dec-
reasing telomerase activity than 5-FU, which did not cause
any significant change. This result may also explain the fact
that cisplatin is a more effective anticancer agent than 5-FU
in the clinical treatment of head and neck cancers. The me-
chanism may be related to the findings in our previous study
(14). In our previous study, when PNUH-12 cells were ex-
posed to cisplatin and 5-FU, cisplatin induced p53-dependent
apoptosis while 5-FU induced p53-dependent and p21WAF1/CIP1
-dependent G1 phase cell-cycle arrest, not apoptosis (14).
However, Ku et al. (15) reported that cisplatin and 5-FU did
not inhibit telomerase activity in nasopharyngeal cancer cell
lines. Although our results for 5-FU are in agreement with
these reports, the results for cisplatin were different. There
is a possibility that different results were achieved as a result
of differences in cell lines and the concentration of anticancer
drugs.
In PNUH-12 and SNU-899, the change of hTERT mRNA
expression after cisplatin and 5-FU exposure was not signif-
icantly correlated with the alteration of telomerase activity.
This means that other mechanisms may exist, such as the
level of gene transcription, post-translational protein-protein
interactions, and protein phosphorylation, for the regulation
of telomerase activity, than hTERT mRNA expression that
was thought as a limiting component of telomerase activity
(16). Lin et al. (16) reported that telomerase activity was
negatively correlated with the hTERT mRNA after treatment
with anti-neoplastic agents in lymphoma cell lines and there
was the potential relationship between p27/Kip 1 and telo-
merase activity. The results of our study correspond with
those of Cressey et al. (13) who reported that hTERT was
not related to a decrease in telomerase activity. In a study
using real-time quantitative RT-PCR assay, Bieche et al. (17)
reported that hTERT mRNA was detected in 100% of breast
tumor RNAs but also in all normal breast RNAs. These
studies suggested that hTERT mRNA itself was not indica-
tive of telomerase activity. 
In addition, in both cell lines, hTR expression increased
when telomerase expression decreased after cisplatin expo-
sure, but hTR expression remained unchanged when the
telomerase expression did not change after 5-FU exposure.
The telomerase activity as a result of cisplatin exposure is
inversely correlated with the level of hTR expression. Our
results differ from those of Cressey et al. (13) who reported
that the expression of hTR was not related to the telomerase
activity following drug-induced cell killing. However, the
increase of hTR is in agreement with results of Rohde et al.
(18) who showed that the expression levels of hTR were found
to be markedly higher in normal renal tissue (no expression
of telomerase activity) than in malignant renal tissue. There
is a possibility that other mechanisms, such as the level of
gene transcription, post-translational protein-protein inter-
actions, and protein phosphorylation, are involved in the reg-
ulation of telomerase activity in PNUH-12 and SNU-899.
These results also suggest the possible existence of a feedback
mechanism, whereby a decrease in telomerase activity results
in the induction of telomerase protein.
The rate limiting component that adjusts telomerase ex-
pression is known to be hTERT mRNA. The results of our
Fig. 4. Detection of hTR in PNUH-12 (A) and SNU-899 (B) samples by real-time RT-PCR analysis using the LightCycler. Concomitant detec-
tion of PBGD mRNA served as a reference for relative quantification. In both cell lines, hTR levels were increased after cisplatin exposure,
but, thy did not change significantly after 5-FU exposure. 
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The reason for this contradiction may be the fact that previ-
ous studies had conducted semi-quantitative evaluation of
hTERT mRNA and hTR expression through RT-PCR (6-8).
The authors used real-time RT-PCR, which could measure
hTERT mRNA and hTR expression quantitatively. The real-
time PCR method makes RNA quantitation much more
precise and reproducible, rather than end point measure-
ment of the amount of accumulated PCR product (19). 
In conclusion, after cisplatin exposure, the telomerase activ-
ity and hTERT mRNA expression in PNUH-12 and SNU-
899 decreased but hTR manifestation increased. After 5-FU
exposure, the changes in telomerase and hTR activity in both
cell lines were insignificant but hTERT mRNA manifesta-
tion decreased. These results suggest that there may be other
important regulating components other than hTERT mRNA
that regulate the telomerase activity in PNUH-12 and SNU-
899. 
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